Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

URN to cite this document:: urn:nbn:de:bvb:355-epub-566442
DOI to cite this document:: 10.5283/epub.56644

Glutsch, Valerie ; Kneitz, Hermann ; Gesierich, Anja ; Goebeler, Matthias ; Haferkamp, Sebastian

; Becker, Jürgen C. ; Ugurel, Selma ; Schilling, Bastian

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 29 Feb 2024 12:35

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Background Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab. For avelumab-refractory patients, efficient and safe treatment options are lacking. Methods At three different sites in Germany, clinical and molecular data of patients with metastatic MCC ...